With regulatory compliance at the core of our ethos, Bright Green stands to incur a massive revenue share of the US$27.97 Billion global plant-based API market—specifically the US$10 Billion spent by the U.S. each year on foreign drug imports.

As support grows among U.S. legislators for the Manufacturing API, Drugs, and Excipients (MADE) in America Act reintroduced in November 2023, Bright Green has the opportunity to become the sole authorized business capable of meeting market demand at scale. 

With expansions underway at our 1 million + sq foot, state-of-the-start Grants New Mexico facility to support the authorized research, production, manufacture, and distribution of APIs and plant-based drugs, our focus is on securing federal government contracts to deliver a predictable, reliable, and uninterrupted supply chain within the U.S.